IFNA1 and breast cancer: While a direct link between ADAR1-mediated RNA editing and immunotherapy response in BC is not established, ADAR1’s role in enhancing neoantigen production and the IFN pathway suggests potential therapeutic targeting to improve immunotherapy outcomes (Figure 3).